NEW REIMAGINED IDENTITY LIFESCIENCES AUSTRALIA REPOSITIONS FOR SECTOR Commences new initiatives in Company Directors training, Standards push and support for Early Career Stage workforce
With
Dr Tim Boyle PhD ChMPP,
Chief Executive Officer
LifeSciences Australia (formerly called ARCS Australia)
SEGMENT
Filmed in Sydney | June 2026
In June 2026, ARCS Australia formally became LifeSciences Australia — a name chosen to reflect the role the organisation plays across Australia’s life sciences sector.
Over more than 40 years, ARCS has grown well beyond its origins as a training and education body for regulatory and clinical specialists. Today, the organisation supports professionals across the entire life sciences sector — from early research through regulation, development and commercialisation — through an expanding range of programs and initiatives.
Following extensive member and stakeholder consultation throughout 2025 the name change was decided aiming to be a clearer, more inclusive identity reflecting the full breadth of Australia’s life sciences workforce and its role as the sector’s professional peak body.
Australian Health Journal was invited to the 2026 ARCS Conference in Sydney and met with Dr Tim Boyle Chief Executive Officer, LifeSciences Australia.
Source: Adapted from the ARCS Australia website
-
AHHA Sidney Sax Medal 2019 Awarded to Vicki Wade
AHHA Sidney Sax Medal 2019 awarded to Vicki Wade
-
Inaugural Rural and Remote Health Awards
Rural communities are a foundation of the economy and society and must be kept healthy.
There are significant personal, professional and financial rewards for rural healthcare professionals. However, there are also challenges – isolation, long hours, confusion about where to turn for support.
To acknowledge and celebrate the work of Rural and Remote Health Professionals, Rural Health Pro have launched the inaugural National Rural and Remote Health Awards.
-
Clinical trial site in primary care setting open for novel therapies in psychiatry
Over the past decade, Paratus has been involved in over 200 clinical trials across 4 clinical site locations. Now a fifth site, the newly opened Melbourne site will cater to both primary care and psychiatry, specifically designed for psychedelic studies.
The new Melbourne site will be a focused on primary care studies specifically expanding access to psychiatric research, a growing area of unmet need. Australian Health Journal met with 3 recent hires brought in to support clinical trials across the organisation and in psychiatry in Melbourne.
